Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:27:33.576Z.
Calculation as of: 2026-10-06T16:27:33.576Z.
Quote observation: 2026-10-06T16:25:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880033b02c1352d2eede0b9825b135807cf5616a7da0006e335be03a15b23327
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$501.13M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$523.60M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$486.60M
EV/EBITDA Ratio
10.48x
TTM Avg
7.79x
3Y Avg
5.90x
5Y Avg
5.85x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 908 Devices Inc. (MASS) | $508.33M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $501.13M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $517.30M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $513.04M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $495.23M | N/A | N/A | N/A | N/A |
| Oculis Holding AG (OCS)vs › | $495.09M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $523.60M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $527.94M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.60M | 10.48x | 7.79x | 5.90x | 5.85x |
| ProKidney Corp. (PROK)vs › | $532.96M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
